Hyperthyroidism  >>  Tepezza (teprotumumab-trbw)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tepezza (teprotumumab-trbw) / Roche, Amgen
NCT01868997 / 2014-000113-31: Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

Completed
2
88
US, Europe
teprotumumab, RV 001, HZN-001, normal saline
Horizon Pharma USA, Inc.
Thyroid Associated Ophthalmopathies, Thyroid-Associated Ophthalmopathy
03/16
02/17

Download Options